Back to Search
Start Over
Olaratumab plus anthracyline in advanced/metastatic soft tissue sarcoma
- Source :
- Wiener klinische Wochenschrift. 133:21-25
- Publication Year :
- 2019
- Publisher :
- Springer Science and Business Media LLC, 2019.
-
Abstract
- e22550 Background: Olaratumab is a humanized monoclonal anti platelet-derived growth factor receptor α antibody that has been approved in combination with doxorubicin for the treatment of patients with metastatic soft tissue sarcoma (STS). The purpose of this retrospective study was to assess the clinical efficacy in STS patients treated with olaratumab in a real-world setting in Austria. Methods: Retrospectively collected, longitudinal data from patients treated between November 2016 and September 2018 at 9 Austrian centers were obtained from respective medical charts. Eligible patients were all patients who received at least one dose of olaratumab. Parameters of most interest collected were response rates, progression-free survival (PFS) and overall survival (OS). Results: Altogether 55 patients were included into analysis. Median age was 58 years. In total, 65.5% (n = 36), 21.8% (n = 12) and 12.7% (n = 7) received olaratumab as first-, second- or ≥ third-line treatment, respectively. Olaratumab was administered either in combination with doxorubicin (81.8%, n = 45) or liposomal doxorubicin (16.4%, n = 9); 1 patient received olaratumab as upfront monotherapy. Median PFS and OS were 2.6 and 11.4 months. The objective response rate was 11.4 % and the disease control rate was 40.9 %. Conclusions: In this real-world analysis outcome was less pronounced compared to the results of the Phase Ib/II approval trial ( Tap WD et al. Lancet 2016). Thus, the results of the ongoing phase III trial (NCT02451943) are urgently needed to confirm the efficacy of the combination of olaratumab and doxorubicin in STS patients.
- Subjects :
- Oncology
Cancer Research
medicine.medical_specialty
030204 cardiovascular system & hematology
03 medical and health sciences
0302 clinical medicine
Growth factor receptor
Internal medicine
Antineoplastic Combined Chemotherapy Protocols
medicine
Humans
Doxorubicin
In patient
030212 general & internal medicine
Clinical efficacy
Retrospective Studies
biology
business.industry
Soft tissue sarcoma
Antibodies, Monoclonal
Sarcoma
Retrospective cohort study
General Medicine
Middle Aged
medicine.disease
Treatment Outcome
Austria
030220 oncology & carcinogenesis
Monoclonal
biology.protein
Cancer research
Antibody
business
030215 immunology
Olaratumab
medicine.drug
Subjects
Details
- ISSN :
- 16137671 and 00435325
- Volume :
- 133
- Database :
- OpenAIRE
- Journal :
- Wiener klinische Wochenschrift
- Accession number :
- edsair.doi.dedup.....54266deb1675ac8072972688fbdc4351